Examkin

Soru

Zorluk: OrtaInfectious Diseases

A patient is hospitalized for the management of an acute, swollen, and exquisitely tender left knee. Diagnostic arthrocentesis performed at admission yielded opaque, purulent synovial fluid, prompting the immediate initiation of empiric antimicrobial therapy with intravenous vancomycin and intravenous ceftriaxone. Over the past 48 hours, the patient has demonstrated marked clinical improvement, with complete resolution of fever and a significant decrease in joint effusion. The microbiology laboratory subsequently contacts the team to report that the admission synovial fluid culture is growing *Streptococcus pyogenes* (Group A Streptococcus). The isolate demonstrates standard susceptibility patterns to all tested beta-lactams, macrolides, and fluoroquinolones. In accordance with the principles of antimicrobial stewardship, which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Transition to intravenous penicillin GCevap
  2. B
    Maintain the current regimen of intravenous vancomycin and ceftriaxone
  3. C
    Discontinue ceftriaxone and maintain intravenous vancomycin
  4. D
    Transition to intravenous piperacillin-tazobactam
  5. E
    Transition to oral trimethoprim-sulfamethoxazole

Cevap

The most appropriate next step is to transition to intravenous penicillin G.
The correct answer is to transition the patient to intravenous penicillin G. The cornerstone of antimicrobial stewardship in the inpatient setting is 'de-escalation.' When a patient presents with a severe, potentially limb- or life-threatening infection (such as septic arthritis), it is appropriate to start broad-spectrum empiric therapy (e.g., vancomycin for MRSA and ceftriaxone for Gram-negative organisms). However, once blood or synovial fluid cultures identify the causative pathogen and its susceptibility profile, the antibiotic regimen MUST be narrowed to the most targeted, effective agent. *Streptococcus pyogenes* (Group A Streptococcus) is exquisitely susceptible to penicillin. Transitioning to penicillin G provides optimal bactericidal activity while minimizing collateral damage to the patient's microbiome and preventing the development of resistant organisms.

Adım Adım Çözüm

1
Identify the pathogen and its typical susceptibility profile.
The pathogen is Streptococcus pyogenes (Group A Streptococcus), which is universally susceptible to penicillin.
Accurate pathogen identification allows for targeted antimicrobial therapy.
2
Evaluate the current empiric antibiotic regimen against the identified pathogen.
The patient is on vancomycin (covers MRSA and other Gram-positives) and ceftriaxone (covers many Gram-negatives and some Gram-positives). This is excessively broad for a confirmed Group A Strep infection.
Empiric regimens are designed to cover all likely pathogens before cultures finalize, but must be narrowed once data is available.
3
Apply principles of antimicrobial stewardship to select the optimal definitive therapy.
Therapy should be de-escalated to the narrowest spectrum agent that is highly effective against the pathogen. Intravenous penicillin G (or ampicillin/cefazolin) is the drug of choice.
Targeted therapy minimizes toxicity, reduces the risk of Clostridioides difficile infection, and prevents the emergence of multi-drug resistant organisms.

Anahtar Kavram

Antimicrobial de-escalation (Stewardship)
Bu soruyu puanla

Konular

Infectious Diseases

Bu konudan daha fazla soru